<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1207210858
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEUKAIR
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Chewable tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Macleods Pharmaceuticals Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Macleods Pharmaceuticals Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1023]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAUDI PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Leukair 4 mg is</strong><br />Leukair 4 mg is a leukotriene receptor antagonist that blocks substances called leukotrienes.</p><p><strong>How Leukair 4 mg works</strong><br />Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes, Leukair 4 mg improves asthma symptoms and helps control asthma.</p><p><strong>When Leukair 4 mg should be used</strong><br />Your doctor has prescribed Leukair 4 mg to treat your child&rsquo;s asthma, preventing asthma symptoms during the day and night.</p><ul><li>Leukair 4 mg is used for the treatment of 2 to 5 year old patients who are not adequately controlled on their medication and need additional therapy.</li><li>Leukair 4 mg may also be used as an alternative treatment to inhaled corticosteroids for 2 to 5 year old patients who have not recently taken oral corticosteroids for their asthma and have shown that they are unable to use inhaled corticosteroids.</li><li>Leukair 4 mg also helps prevent the narrowing of airways triggered by exercise for patients 2 years of age and older.</li></ul><p>Your doctor will determine how Leukair 4 mg should be used depending on the symptoms and severity of your child&rsquo;s asthma.</p><p><strong>What is asthma?</strong><br />Asthma is a long-term disease.</p><p>Asthma includes:</p><ul><li>difficulty breathing because of narrowed airways. This narrowing of airways worsens and improves in response to various conditions.</li><li>sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.</li><li>swelling (inflammation) in the lining of airways.</li></ul><p>Symptoms of asthma include: Coughing, wheezing, and chest tightness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor about any medical problems or allergies your child has now or has had.</p><p><strong>Do not give Leukair 4 mg to your child</strong></p><ul><li>If he/she is allergic to montelukast or any of the other ingredients of this medicine (listed in section 6).</li></ul><p><strong>Warnings and Precautions</strong><br />Talk to your doctor or pharmacist before you give Leukair 4 mg to your child.</p><ul><li>If your child&rsquo;s asthma or breathing gets worse, tell your doctor immediately.</li><li>Oral Leukair 4 mg is not meant to treat acute asthma attacks. If an attack occurs, follow the instructions your doctor has given you for your child. Always have your child&rsquo;s inhaled rescue medicine for asthma attacks with you.</li><li>It is important that your child take all asthma medications prescribed by your doctor. Leukair 4 mg should not be used instead of other asthma medications your doctor has prescribed for your child.</li><li>If your child is on anti-asthma medicines, be aware that if he/she develops a combination of symptoms such as a flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.</li><li>Your child should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines (also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make his/her asthma worse.</li></ul><p>Patients should be aware that various neuropsychiatric events (for example behaviour and mood-related changes) have been reported in adults, adolescents and children with Leukair 4 mg (see section 4). If you or your child develop such symptoms while taking Leukair 4 mg, you should consult your doctor.</p><p><strong>Children and adolescents</strong><br />Do not give this medicine to children less than 2 years of age.</p><p>There are different form(s) of this medicine available for paediatric patients under 18 years of age based on age range.</p><p><strong>Other medicines and Leukair 4 mg</strong><br />Tell your doctor or pharmacist if your child is taking or has recently been given or might be given any other medicines including those obtained without a prescription.<br />Some medicines may affect how Leukair 4 mg works, or Leukair 4 mg may affect how your child&rsquo;s other medicines work.<br />Tell your doctor if your child is taking the following medicines before starting Leukair 4 mg:</p><ul><li>phenobarbital (used for treatment of epilepsy)</li><li>phenytoin (used for treatment of epilepsy)</li><li>rifampicin (used to treat tuberculosis and some other infections)</li></ul><p><strong>Leukair 4 mg with food, drink and alcohol</strong><br />Leukair 4 mg Chewable Tablets should not be taken immediately with food; it should be taken at least 1 hour before or 2 hours after food.</p><p><strong>Pregnancy and breast-feeding</strong><br />This subsection is not applicable for the Leukair 4 mg Chewable Tablets since they are intended for use in children 2 to 5 years of age.<strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong><br />This subsection is not applicable for the Leukair 4 mg Chewable Tablets since they are intended for use in children 2 to 5 years of age, however the following information is relevant to the active ingredient, montelukast.<br />Montelukast is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported with Montelukast may affect some patients&rsquo; ability to drive or operate machinery.</p><p><strong>Leukair 4 mg Chewable Tablets contain aspartame, a source of phenylalanine</strong><br />If your child has phenylketonuria (a rare, hereditary disorder of the metabolism) you should take into account that each 4 mg chewable tablet contains phenylalanine (equivalent to 0.674 mg phenylalanine per 4 mg chewable tablet).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always have your child take this medicine exactly as your doctor or pharmacist has told you. Check with your child&rsquo;s doctor or pharmacist if you are not sure.</p><ul><li>This medicine is to be given to a child under adult supervision.</li><li>Your child should take only one chewable tablet of Leukair 4 mg once a day as prescribed by your doctor.</li><li>It should be taken even when your child has no symptoms or if he/she has an acute asthma attack.</li></ul><p><strong>For children 2 to 5 years of age:</strong><br />The recommended dose is one 4 mg chewable tablet daily to be taken in the evening.</p><p>If your child is taking Leukair 4 mg, be sure that he/she does not take any other medicines that contain the same active ingredient, montelukast.</p><p>This medicine is for oral use.<br />The tablets are to be chewed before swallowing.<br />Leukair 4 mg Chewable Tablets should not be taken immediately with food; it should be taken at least 1 hour before or 2 hours after food.</p><p><strong>If your child takes more Leukair 4 mg than he/she should</strong><br />Contact your child&rsquo;s doctor immediately for advice.<br />There were no side effects reported in the majority of overdose reports. The most frequently occurring symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.</p><p><strong>If you forget to give Leukair 4 mg to your child</strong><br />Try to give Leukair 4 mg as prescribed. However, if your child misses a dose, just resume the usual schedule of one chewable tablet once daily.<br />Do not give a double dose to make up for a forgotten dose.</p><p><strong>If your child stops taking Leukair 4 mg</strong><br />Leukair 4 mg can treat your child&rsquo;s asthma only if he/she continues taking it.<br />It is important for your child to continue taking Leukair 4 mg for as long as your doctor prescribes. It will help control your child&rsquo;s asthma.</p><p>If you have any further questions on the use of this medicine, ask your child&rsquo;s doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>In clinical studies with montelukast 4 mg chewable tablets, the most commonly reported side effects (may affect up to 1 in 10 people) thought to be related to montelukast were:</p><ul><li>abdominal pain</li><li>thirst</li></ul><p>Additionally, the following side effect was reported in clinical studies with montelukast 10 mg film-coated tablets:</p><ul><li>headache</li></ul><p>These were usually mild and occurred at a greater frequency in patients treated with montelukast than placebo (a pill containing no medication).</p><p><strong>Serious side effects</strong><br />Talk with your doctor immediately if you notice any of the following side effects, which may be serious, and for which you may need urgent medical treatment.</p><p>Uncommon: the following may affect up to 1 in 100 people</p><ul><li>allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing</li><li>behaviour and mood related changes: agitation including aggressive behaviour or hostility, depression</li><li>seizure</li></ul><p>Rare: the following may affect up to 1 in 1,000 people</p><ul><li>increased bleeding tendency</li><li>tremor</li><li>palpitations</li></ul><p>Very rare: the following may affect up to 1 in 10,000 people</p><ul><li>combination of symptoms such as flu-like illness, pins and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) (see Section 2)</li><li>low blood platelet count</li><li>behaviour and mood related changes: hallucinations, disorientation, suicidal thoughts and actions</li><li>swelling (inflammation) of the lungs</li><li>severe skin reactions (erythema multiforme) that may occur without warning</li><li>inflammation of the liver (hepatitis)</li></ul><p><strong>Other side effects while the medicine has been on the market</strong></p><p>Very common: the following may affect more than 1 in 10 people</p><ul><li>upper respiratory infection</li></ul><p>Common: the following may affect up to 1 in 10 people</p><ul><li>diarrhoea, nausea, vomiting</li><li>rash</li><li>fever</li><li>elevated liver enzymes</li></ul><p>Uncommon: the following may affect up to 1 in 100 people</p><ul><li>behaviour and mood related changes: dream abnormalities, including nightmares, trouble sleeping, sleepwalking, irritability, feeling anxious, restlessness</li><li>dizziness, drowsiness, pins and needles/numbness</li><li>nosebleed</li><li>dry mouth, indigestion</li><li>bruising, itching, hives</li><li>joint or muscle pain, muscle cramps</li><li>bedwetting in children</li><li>weakness/tiredness, feeling unwell, swelling</li></ul><p>Rare: the following may affect up to 1 in 1,000 people</p><ul><li>behaviour and mood related changes: disturbance in attention, memory impairment, uncontrolled muscle movements</li></ul><p>Very rare: the following may affect up to 1 in 10,000 people</p><ul><li>tender red lumps under the skin, most commonly on your shins (erythema nodosum)</li><li>behaviour and mood related changes: obsessive-compulsive symptoms, stuttering</li></ul><p>If your child gets any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not store above 30&deg;C.<br />Store in a dry place. Protect from light.<br />Do not use this medicine after the expiry date which is stated on the strip and carton. The expiry date refers to the last day of that month.<br />Do not throw away any medicines via wastewater or household waste. Ask the pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is montelukast. Each chewable tablet contains montelukast sodium which corresponds to 4 mg of montelukast.</li><li>The other ingredients are: Microcrystalline cellulose, mannitol, croscarmellose sodium, ferric oxide red, hydroxypropyl cellulose, disodium EDTA, purified water, aspartame, cherry flavor, magnesium stearate.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Leukair 4 mg chewable tablets are pink colour, oval, biconvex, uncoated chewable mottled tablet debossed with ‘CL 55’ on one side and plain on the other side.
Leukair 4 mg is available as 30 chewable tablets carton pack containing 3 strips (10 tablets each).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saudi Pharmaceutical Industries<br />P.O. Box No.: 355127, Riyadh 11383<br />Kingdom of Saudi Arabia.<br />Tel: (+96611) 2650450, 2650354<br />Fax: (+96611) 2650383<br />Email: info@saudi-pharma.net<strong>&nbsp;</strong></p><p><strong>Manufacturer</strong><br />Macleods Pharmaceuticals Limited<br />Block N-2, Village Theda,<br />Post Office Lodhimajra, Tehsil Baddi,<br />Distt. Solan, Himachal Pradesh - 174101, India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو ليوكير 4 ملغ</strong><br />ليوكير 4 ملغ هو مضاد لمستقبلة اللوكوتريين حيث يقوم بإحصار مواد تدعى لوكوتريينات.</p><p dir="RTL"><strong>كيف يعمل ليوكير 4 ملغ</strong><br />تسبب اللوكوتريينات تضيقاً وتورماً في المسالك الهوائية في الرئتين. ومن خلال إحصار اللوكوتريينات فإن ليوكير 4 ملغ يحسن أعراض الربو ويساعد في السيطرة على الربو.</p><p dir="RTL"><strong>متى يجب استخدام ليوكير 4 ملغ</strong><br />لقد قام طبيبك بوصف ليوكير 4 ملغ ليعالج الربو لدى طفلك أو يقيه من أعراض الربو خلال النهار والليل.</p><ul dir="rtl"><li>يستخدم ليوكير 4 ملغ لمعالجة المرضى بعمر 2 إلى 5 سنوات الذين لا تتم السيطرة على المرض عندهم بشكل كاف من خلال أدويتهم التي يستخدمونها ويحتاجون إلى معالجة إضافية.</li><li>يمكن أن يستخدم ليوكير 4 ملغ أيضاً كمعالجة بديلة للكورتيكوستيرويدات الاستنشاقية للمرضى بعمر 2 إلى 5 سنوات الذين لم يتناولوا مؤخراً كورتيكوستيرويدات فموية للربو وأظهروا عدم القدرة على استخدام الكورتيكوستيرويدات الاستنشاقية.</li><li>يساعد ليوكير 4 ملغ أيضاً على الوقاية من تضيق المسالك الهوائية الناجم عن التمرين عند المرضى بعمر سنتين أو أكثر.</li></ul><p dir="RTL">سيقوم طبيبك بتحديد كيفية استخدام ليوكير 4 ملغ اعتماداً على أعراض وشدة الربو لدى طفلك.</p><p dir="RTL"><strong>ما هو الربو؟</strong><br />الربو مرض طويل الأمد.</p><p dir="RTL">يتضمن الربو:</p><ul dir="rtl"><li>صعوبة في التنفس بسبب تضيق المسالك الهوائية. هذا التضيق في المسالك الهوائية يسوء ويتحسن استجابة للظروف المختلفة.</li><li>مسالك هوائية حساسة تستجيب لأشياء عديدة، مثل دخان السجائر أو غبار الطلع أو الهواء البارد أو التمرين.</li><li>تورماً (التهاباً) في بطانة المسالك الهوائية.</li></ul><p>تتضمن أعراض الربو: سعالاً وأزيزاً وضيقاً في الصدر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أخبر طبيبك عن أية مشاكل طبية أو حالات تحسسية يعاني منها طفلك في الوقت الحالي أو قد عانى منها سابقاً.</p><p dir="RTL"><strong>لا تعط ليوكير 4 ملغ لطفلك</strong></p><ul dir="rtl"><li>إذا كان حساساً لمونتيلوكاست أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</li></ul><p dir="RTL"><strong>&nbsp;تحذيرات واحتياطات</strong><br />تكلم مع طبيبك أو الصيدلي قبل إعطاء ليوكير 4 ملغ لطفلك.</p><ul dir="rtl"><li>إذا كان الربو أو التنفس لدى طفلك يزدادان سوءاً فأخبر طبيبك على الفور.</li><li>لا يعتبر ليوكير 4 ملغ عن طريق الفم علاجاً لنوبات الربو الحادة. إذا حدثت نوبة ربو فاتبع التعليمات التي أوصى بها طبيبك لطفلك. أبق معك دائماً دواء طفلك الاستنشاقي الإسعافي الذي تستخدمه لنوبات الربو.</li><li>من المهم بأن يتناول طفلك جميع علاجات الربو الموصوفة من قبل طبيبك. يجب ألا تستبدل علاجات الربو الأخرى التي وصفها طبيبك لطفلك بليوكير 4 ملغ.</li><li>يجب عليك إذا كنت تستخدم لطفلك علاجاً مضاداً للربو أن تكون حذراً إذا تطور لديه مزيج من الأعراض مثل الأعراض المماثلة للأنفلونزا و/أو الإحساس بما يشبه وخز الدبابيس والإبر أو النمل في الذراعين أو الساقين و/أو ازدياد سوء الأعراض الرئوية و/أو الطفح، ويجب عليك استشارة طبيبك.</li><li>يجب على طفلك ألا يتناول حمض الأسيتيل ساليسيليك (الأسبرين) أو الأدوية المضادة للالتهاب (المعروفة أيضاً بمضادات الالتهاب اللاستيرويدية أو NSAIDs) إذا كانت تزيد سوء حالة الربو لديه.</li></ul><p dir="RTL">يجب أن يكون المرضى على دراية بأنه تم الإبلاغ عن العديد من الحوادث النفسية العصبية مثل (التغيرات المتعلقة بالسلوك والمزاج) لدى البالغين والمراهقين والأطفال الذين يستخدمون ليوكير 4 ملغ (انظر القسم 4). إذا ظهرت عليك أو على طفلك مثل هذه الأعراض أثناء تناول ليوكير 4 ملغ، فيجب عليك استشارة طبيبك.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong><br />لا تعطِ هذا الدواء للأطفال بعمر أقل من سنتين.<br />تتوفر أشكال مختلفة من هذا الدواء للمرضى الأطفال بعمر أقل من 18 سنة اعتماداً على مجال العمر.</p><p dir="RTL"><strong>الأدوية الأخرى وليوكير 4 ملغ</strong><br />أخبر طبيبك أو الصيدلي إذا كان طفلك يتناول أو قد تناول مؤخراً أو ربما يتناول أدوية أخرى بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية.<br />قد تؤثر بعض الأدوية على آلية عمل ليوكير 4 ملغ أو قد يؤثر ليوكير 4 ملغ على آلية عمل أدوية طفلك الأخرى.<br />أخبر طبيبك إذا كان طفلك يتناول الأدوية التالية قبل أن تبدأ باستخدام ليوكير 4 ملغ:</p><ul dir="rtl"><li>فينوباربيتال (يستخدم لمعالجة الصرع).</li><li>فينيتوين (يستخدم لمعالجة الصرع).</li><li>ريفامبيسين (يستخدم لمعالجة السل وبعض العداوى الأخرى).</li></ul><p dir="RTL"><strong>ليوكير 4 ملغ مع الطعام والشراب والكحول</strong><br />يجب ألا يتم تناول ليوكير 4 ملغ أقراص قابلة للمضغ مع الطعام مباشرة؛ بل ينبغي تناولها قبل الطعام بساعة أو بعده بساعتين على الأقل.</p><p dir="RTL"><strong>الحمل والإرضاع</strong><br />هذا القسم لا ينطبق على استخدام ليوكير 4 ملغ أقراص قابلة للمضغ حيث أنها مخصصة للاستخدام في الأطفال بعمر 2 إلى 5 سنوات.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />هذا القسم لا ينطبق على استخدام ليوكير 4 ملغ أقراص قابلة للمضغ حيث أنها مخصصة للاستخدام في الأطفال بعمر 2 إلى 5 سنوات، ومع ذلك فإن المعلومات التالية مرتبطة بالمكون الفعال مونتيلوكاست.<br />من غير المتوقع أن يؤثر مونتيلوكاست على قدرتك على قيادة السيارة أو تشغيل الآلات. وعلى أية حال فقد تختلف الاستجابات الفردية تجاه الدواء. إن بعض الأعراض الجانبية (مثل الدوخة والنعاس) التي تم تسجيل حدوثها مع استخدام مونتيلوكاست قد تؤثر على قدرة بعض المرضى على القيادة أو تشغيل الآلات.</p><p dir="RTL"><strong>ليوكير 4 ملغ أقراص قابلة للمضغ يحتوي على الأسبارتام وهو مصدر لفينيل ألانين</strong><br />إذا كان طفلك مصاباً ببيلة الفينيل كيتون (اضطراب استقلابي وراثي نادر) فعليك أن تأخذ في الحسبان أن قرص 4 ملغ القابل للمضغ يحتوي على فينيل ألانين (يكافئ 0.674 ملغ من فينيل ألانين في قرص 4 ملغ القابل للمضغ).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دع طفلك يتناول هذا الدواء دائماً كما أخبرك طبيبك أو الصيدلي. يجب أن تراجع طبيب طفلك أو الصيدلي إذا لم تكن متأكداً.</p><ul dir="rtl"><li>يجب أن يعطى هذا الدواء للطفل تحت إشراف شخص بالغ.</li><li>يجب على طفلك تناول قرص واحد فقط قابل للمضغ من ليوكير 4 ملغ مرة واحدة يومياً كما وصف طبيبك.</li><li>يجب أن يقوم بتناوله إن لم تكن لدى طفلك أعراض أو إذا كان طفلك يعاني من نوبة ربو حادة على حد سواء.</li></ul><p dir="RTL"><strong>الأطفال بعمر 2 إلى 5 سنوات:</strong><br />الجرعة الموصى بها هي قرص واحد 4 ملغ قابل للمضغ يؤخذ يومياً في المساء.<br />إذا كان طفلك يتناول ليوكير 4 ملغ فتأكد من أنه لا يتناول أي دواء آخر يحتوي على المكون الفعال نفسه، مونتيلوكاست.</p><p>هذا الدواء يستخدم عن طريق الفم.<br />يجب مضغ الأقراص قبل بلعها.<br />يجب ألا يتم تناول ليوكير 4 ملغ أقراص قابلة للمضغ مع الطعام مباشرة؛ بل ينبغي تناولها قبل الطعام بساعة أو بعده بساعتين على الأقل.</p><p><strong>إذا تناول طفلك ليوكير 4 ملغ أكثر مما ينبغي</strong><br />اتصل بطبيب طفلك في الحال للحصول على المشورة الطبية.<br />لم يسجل حدوث أعراض جانبية في معظم تقارير الجرعة الزائدة. تضمنت الحوادث المسجلة الأكثر تكراراً للجرعة الزائدة لدى البالغين والأطفال الألم البطني والنعاس والعطش والصداع والقيء وفرط النشاط.</p><p dir="RTL"><strong>إذا نسيت أن تعطي ليوكير 4 ملغ لطفلك</strong><br />حاول أن تعطي ليوكير 4 ملغ كما وصف لطفلك. على أية حال، إذا نسيت إعطاء جرعة لطفلك فعليك فقط أن تستأنف الجدول اليومي المعتاد لقرص واحد قابل للمضغ مرة واحدة يومياً.<br />لا تعط جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>إذا توقفت طفلك عن تناول ليوكير 4 ملغ</strong><br />يمكن لليوكير 4 ملغ أن يعالج الربو لدى طفلك فقط إذا استمر في تناوله.<br />من المهم لطفلك أن يستمر في تناول ليوكير 4 ملغ طوال المدة التي يحددها طبيبك. لأن ذلك سيساعد في السيطرة على الربو لدى طفلك.<br />إذا كانت لديك أية أسئلة أخرى حول استخدام هذا الدواء فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب أعراضاً جانبية إلا أنها قد لا تحدث لدى كل الأشخاص.<br />في الدراسات السريرية على مونتيلوكاست 4 ملغ أقراص قابلة للمضغ، وجد أن الأعراض الجانبية المسجلة الأكثر شيوعاً (قد تؤثر على 1 من 10 أشخاص) التي يعتقد ارتباطها بمونتيلوكاست هي:</p><ul dir="rtl"><li>ألم بطني</li><li>عطش</li></ul><p dir="RTL">بالإضافة إلى ذلك، تم تسجيل العرض الجانبي التالي في الدراسات السريرة على مونتيلوكاست 10 ملغ أقراص مغلفة:</p><ul dir="rtl"><li>صداع</li></ul><p dir="RTL">تكون هذه الأعراض عادة خفيفة وتحدث بمعدل أكبر لدى المرضى الذين تمت معالجتهم بمونتيلوكسات مقارنة بأولئك الذين تناولوا دواء وهمياً (أقراصاً لا تحتوي على دواء).</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة</strong><br />تحدث إلى طبيبك على الفور إذا لاحظت أياً من الأعراض الجانبية التالية، التي قد تكون خطيرة، وقد تحتاج إلى معالجة طبية عاجلة.<br />غير شائعة: الأعراض التالية قد تؤثر على 1 من 100 شخص</p><ul dir="rtl"><li>تفاعلات تحسسية تتضمن تورماً في الوجه و/أو الشفاه و/أو اللسان و/أو الحلق والتي يمكن أن تسبب صعوبة في التنفس أو البلع</li><li>تغيرات متعلقة بالسلوك والمزاج: هياج يشتمل على سلوك عدواني أو حقد، اكتئاب</li><li>نوبة</li></ul><p dir="RTL">نادرة: الأعراض التالية قد تؤثر على 1 من 1000 شخص</p><ul dir="rtl"><li>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة قابلية النزف</li><li>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رعاش</li><li>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان</li></ul><p dir="RTL">نادرة جداً: الأعراض التالية قد تؤثر على 1 من 10000 شخص</p><ul dir="rtl"><li>مزيج من الأعراض مثل الأعراض المماثلة للأنفلونزا و/أو الإحساس بما يشبه وخز الدبابيس والإبر أو النمل في الذراعين والساقين و/أو ازدياد سوء الأعراض الرئوية و/أو طفح (متلازمة شيرغ-ستراوس). (انظر القسم 2).</li><li>انخفاض تعداد الصفيحات الدموية</li><li>تغيرات متعلقة بالسلوك والمزاج: هلوسات، توهان، أفكار وأفعال انتحارية</li><li>تورم (التهاب) الرئتين</li><li>ردود فعل جلدية شديدة (حمامى عديدة الأشكال) قد تحدث دون سابق إنذار</li><li>التهاب الكبد</li></ul><p dir="RTL"><strong>الأعراض الجانبية الأخرى بعد طرح الدواء في السوق</strong></p><p dir="RTL">شائعة جداً: الأعراض التالية قد تؤثر على أكثر من 1 من 10 أشخاص</p><ul dir="rtl"><li>عدوى بالجهاز التنفسي العلوي</li></ul><p dir="RTL">شائعة: الأعراض التالية قد تؤثر على 1 من 10 أشخاص</p><ul dir="rtl"><li>إسهال، غثيان، قيء</li><li>طفح</li><li>حمى</li><li>ارتفاع إنزيمات الكبد</li></ul><p dir="RTL">غير شائعة: الأعراض التالية قد تؤثر على 1 من 100 شخص</p><ul dir="rtl"><li>تغيرات متعلقة بالسلوك والمزاج: اضطرابات في الأحلام تشتمل على كوابيس، اضطراب النوم، المشي أثناء النوم، تهيج، شعور بالقلق، تململ</li><li>دوخة، نعاس، إحساس بما يشبه وخز الدبابيس والإبر/نمل</li><li>رعاف</li><li>جفاف الفم، عسر الهضم</li><li>تكدم، حكة، شرى</li><li>ألم في المفاصل أو العضلات، تقلصات عضلية</li><li>تبول في الفراش لدى الأطفال</li><li>ضعف/تعب، شعور بالتوعك، تورم</li></ul><p dir="RTL">نادرة: الأعراض التالية قد تؤثر على 1 من 1000 شخص</p><ul dir="rtl"><li>تغيرات متعلقة بالسلوك والمزاج: اضطراب في الانتباه، ضعف في الذاكرة، حركات عضلية غير منضبطة</li></ul><p dir="RTL">نادرة جداً: الأعراض التالية قد تؤثر على 1 من 10000 شخص</p><ul dir="rtl"><li>كتل حمراء طرية تحت الجلد، (حُمامى عَقِدة) شائعة بكثرة على قصبتي الساقين (عظام الظنبوب)</li><li>تغيرات متعلقة بالسلوك والمزاج: أعراض الوسواس القهري، التأتأة (التلعثم)</li></ul><p>إذا أصيب طفلك بأية أعراض جانبية فتحدث إلى طبيبك أو الصيدلي أو الممرض. هذا يشمل أيضاً أية أعراض جانبية محتملة غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيداً عن متناول ومرأى الأطفال.<br />يخزن عند حرارة لا تزيد عن 30&deg;م.<br />يخزن في مكان جاف. يحفظ بعيداً عن الضوء.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على الشريط والعبوة الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.<br />لا تقم بالتخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تحتاجها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>المادة الفعالة هي مونتيلوكاست. يحتوي كل قرص قابل للمضغ على مونتيلوكاست صوديوم ما يكافئ 4 ملغ من مونتيلوكاست.</li><li>المكونات الأخرى هي: السلولوز البلوري المكروي، مانيتول، صوديوم كروس كارميلوز، أكسيد الحديد الأحمر، هيدروكسي بروبيل سلولوز، إيديتات ثنائية الصوديوم، ماء منقى، أسبارتام، نكهة الكرز، ستيارات المغنيزيوم.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص ليوكير 4 ملغ القابلة للمضغ عبارة عن أقراص وردية اللون بيضوية محدبة الوجهين غير مغلفة مبقعة قابلة للمضغ مطبوع عليها &quot;CL 55&quot; على جانب وبدون طباعة على الجانب الآخر.<br />يتوفر ليوكير 4 ملغ في عبوات كرتونية تحتوي على 30 قرصاً قابلاً للمضغ في 3 أشرطة (10 أقراص في كل شريط).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة السعودية للصناعات الصيدلانية<br />صندوق بريد رقم: 355127، الرياض 11383<br />المملكة العربية السعودية.<br />هاتف: 2650354، 2650450 (96611+)<br />فاكس: 2650383 (96611+)<br />بريد الكتروني: info@saudi-pharma.net</p><p dir="RTL"><strong>اسم وعنوان المصنع</strong><br />ماكلويدز فارماسوتيكال ليميتد<br />الكتلة رقم 2، بلدة ثيدا<br />مكتب بريد لوديماجرا، تهسيل بادي<br />حي سولان، هيماتشال براديش &ndash; 174101، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Leukair 4 mg chewable tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One chewable tablet contains montelukast sodium, which is equivalent to 4 mg montelukast.
Excipient with known effect: This medicine contains 1.2 mg aspartame per tablet.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Chewable tablet.
Pink colour, oval, biconvex, uncoated chewable mottled tablet debossed with ‘CL 55’ on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Leukair 4 mg is indicated in the treatment of asthma as add-on therapy in those 2 to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &ldquo;as-needed&rdquo; short acting &beta;-agonists provide inadequate clinical control of asthma.<br />Leukair 4 mg may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.2).<br />Leukair 4 mg is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br />This medicinal product is to be given to a child under adult supervision. The recommended dose for paediatric patients 2 - 5 years of age is one 4 mg chewable tablet daily to be taken in the evening. If taken in connection with food, Leukair 4 mg should be taken 1 hour before or 2 hours after food. No dosage adjustment within this age group is necessary.</p><p><u>General recommendations</u><br />The therapeutic effect of Leukair 4 mg on parameters of asthma control occurs within one day. Patients should be advised to continue taking Leukair 4 mg even if their asthma is under control, as well as during periods of worsening asthma.<br />No dosage adjustment is necessary for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.</p><p><u>Leukair 4 mg as an alternative treatment option to low-dose inhaled corticosteroids for mild, persistent asthma</u><br />Montelukast is not recommended as monotherapy in patients with moderate persistent asthma. The use of montelukast as an alternative treatment option to low-dose inhaled corticosteroids for children with mild persistent asthma should only be considered for patients who do not have a recent history of serious asthma attacks that required oral corticosteroid use and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.1). Mild persistent asthma is defined as asthma symptoms more than once a week but less than once a day, nocturnal symptoms more than twice a month but less than once a week, normal lung function between episodes. If satisfactory control of asthma is not achieved at follow-up (usually within one month), the need for an additional or different anti-inflammatory therapy based on the step system for asthma therapy should be evaluated. Patients should be periodically evaluated for their asthma control.</p><p><u>Leukair 4 mg as prophylaxis of asthma for 2 to 5 year old patients in whom the predominant component is exercise-induced bronchoconstriction</u><br />In 2 to 5 year old patients, exercise-induced bronchoconstriction may be the predominant manifestation of persistent asthma that requires treatment with inhaled corticosteroids. Patients should be evaluated after 2 to 4 weeks of treatment with montelukast. If satisfactory response is not achieved, an additional or different therapy should be considered.</p><p><u>Therapy with Leukair 4 mg in relation to other treatments for asthma</u><br />When treatment with Leukair 4 mg is used as add-on therapy to inhaled corticosteroids, Leukair 4 mg should not be abruptly substituted for inhaled corticosteroids (see section 4.4).<br />10 mg film-coated tablets are available for adults and adolescents 15 years of age and older.</p><p><em>Paediatric population</em><br />Do not give Leukair 4 mg chewable tablets to children less than 2 years of age. The safety and efficacy of Leukair 4 mg chewable tablets in children less than 2 years of age has not been established.<br />5 mg chewable tablets are available for paediatric patients 6 to 14 years of age.</p><p><u>Method of administration</u><br />Oral use.<br />The tablets are to be chewed before swallowing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled &beta;-agonist should be used. Patients should seek their doctors&#39; advice as soon as possible if they need more inhalations of short-acting &beta;-agonists than usual.<br />Montelukast should not be abruptly substituted for inhaled or oral corticosteroids.<br />There are no data demonstrating that oral corticosteroids can be reduced when montelukast is given concomitantly.<br />In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases have been sometimes associated with the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship with leukotriene receptor antagonism has not been established, physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.<br />Treatment with montelukast does not alter the need for patients with aspirin-sensitive asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.<br />Leukair 4 mg contains aspartame, a source of phenylalanine. Patients with phenylketonuria should take into account that each 4 mg chewable tablet contains phenylalanine in an amount equivalent to 0.674 mg phenylalanine per dose.<br />Neuropsychiatric events have been reported in adults, adolescents, and children taking Leukair 4 mg (see section 4.8). Patients and physicians should be alert for neuropsychiatric events. Patients and/or caregivers should be instructed to notify their physician if these changes occur. Prescribers should carefully evaluate the risks and benefits of continuing treatment with Leukair 4 mg if such events occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.<br />The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when montelukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.<br /><em>In vitro</em> studies have shown that montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolized by CYP 2C8) demonstrated that montelukast does not inhibit CYP 2C8 <em>in vivo</em>. Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide).<br /><em>In vitro</em> studies have shown that montelukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased the systemic exposure of montelukast by 4.4-fold. No routine dosage adjustment of montelukast is required upon co-administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.<br />Based on <em>in vitro</em> data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of montelukast.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.<br />Limited data from available pregnancy databases do not suggest a causal relationship between montelukast and malformations (i.e. limb defects) that have been rarely reported in worldwide post-marketing experience.<br />Montelukast may be used during pregnancy only if it is considered to be clearly essential.</p><p><u>Breast-feeding</u><br />Studies in rats have shown that montelukast is excreted in milk (see section 5.3). It is unknown whether montelukast/metabolites are excreted in human milk.<br />Montelukast may be used in breast-feeding mothers only if it is considered to be clearly essential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has no or negligible influence on the ability to drive and use machines. However, individuals have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has been evaluated in clinical studies as follows:</p><ul><li>10 mg film-coated tablets in approximately 4,000 adult and adolescent patients 15 years of age and older,</li><li>5 mg chewable tablets in approximately 1,750 paediatric asthmatic patients 6 to 14 years of age, and</li><li>4 mg chewable tablets in 851 paediatric patients 2 to 5 years of age.</li></ul><p>Montelukast has been evaluated in a clinical study in patients with intermittent asthma as follows:</p><ul><li>4 mg granules and chewable tablets in 1,038 paediatric patients 6 months to 5 years of age</li></ul><p>The following drug-related adverse reactions in clinical studies were reported commonly (&ge;1/100 to &lt;1/10) in patients treated with montelukast and at a greater incidence than in patients treated with placebo:</p><table border="1" cellspacing="0" cellpadding="0" style="width:616px"><tbody><tr><td><p><strong>Body System Class</strong></p></td><td><p><strong>Adult and Adolescent Patients 15 years and older (two 12-week studies; n=795)</strong></p></td><td><p><strong>Paediatric Patients 6 to 14 years old</strong></p><p><strong>(one 8-week study; n=201)</strong></p><p><strong>(two 56-week studies; n=615)</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric Patients 2 to 5 years old</strong></p><p><strong>(one 12-week study; n=461)</strong></p><p><strong>(one 48-week study; n=278)</strong></p></td></tr><tr><td><p><strong>Nervous system disorders</strong></p></td><td><p>Headache</p></td><td><p>Headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p><strong>Gastro-intestinal disorders</strong></p></td><td><p>Abdominal pain</p></td><td><p>&nbsp;</p></td><td><p>Abdominal pain</p></td></tr><tr><td><p><strong>General disorders and administration site conditions</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Thirst</p></td></tr></tbody></table><p>With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12 months for paediatric patients 6 to 14 years of age, the safety profile did not change.<br />Cumulatively, 502 paediatric patients 2 to 5 years of age were treated with montelukast for at least 3 months, 338 for 6 months or longer, and 534 patients for 12 months or longer. With prolonged treatment, the safety profile did not change in these patients either.</p><p><u>Tabulated list of Adverse Reactions</u><br />Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse Reactions, in the table below. Frequency Categories were estimated based on relevant clinical trials.</p><table border="1" cellspacing="0" cellpadding="0" style="width:616px"><tbody><tr><td><p><strong>System Organ Class</strong></p></td><td><p><strong>Adverse Reactions</strong></p></td><td><p><strong>Frequency Category*</strong></p></td></tr><tr><td><p>Infections and infestations</p></td><td><p>upper respiratory infection<sup>&dagger;</sup></p></td><td><p>Very Common</p></td></tr><tr><td rowspan="2"><p>Blood and lymphatic system disorders</p></td><td><p>increased bleeding tendency</p></td><td><p>Rare</p></td></tr><tr><td><p>thrombocytopenia</p></td><td><p>Very Rare</p></td></tr><tr><td rowspan="2"><p>Immune system disorders</p></td><td><p>hypersensitivity reactions including anaphylaxis</p></td><td><p>Uncommon</p></td></tr><tr><td><p>hepatic eosinophilic infiltration</p></td><td><p>Very Rare</p></td></tr><tr><td rowspan="3"><p>Psychiatric disorders</p></td><td><p>dream abnormalities including nightmares, insomnia, somnambulism, anxiety, agitation including aggressive behaviour or hostility, depression, psychomotor hyperactivity (including irritability, restlessness, tremor<sup>&sect;</sup>)</p></td><td><p>Uncommon</p></td></tr><tr><td><p>disturbance in attention, memory impairment, tic</p></td><td><p>Rare</p></td></tr><tr><td><p>hallucinations, disorientation, suicidal thinking and behaviour (suicidality), obsessive-compulsive symptoms, dysphemia</p></td><td><p>Very Rare</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>dizziness, drowsiness, paraesthesia/hypoesthesia, seizure</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Cardiac disorders</p></td><td><p>palpitations</p></td><td><p>Rare</p></td></tr><tr><td rowspan="3"><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>epistaxis</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Churg-Strauss Syndrome (CSS) (see section 4.4)</p></td><td><p>Very Rare</p></td></tr><tr><td><p>pulmonary eosinophilia</p></td><td><p>Very Rare</p></td></tr><tr><td rowspan="2"><p>Gastrointestinal disorders</p></td><td><p>diarrhoea<sup>&Dagger;</sup>, nausea<sup>&Dagger;</sup>, vomiting<sup>&Dagger;</sup></p></td><td><p>Common</p></td></tr><tr><td><p>dry mouth, dyspepsia</p></td><td><p>Uncommon</p></td></tr><tr><td rowspan="2"><p>Hepatobiliary disorders</p></td><td><p>elevated levels of serum transaminases (ALT, AST)</p></td><td><p>Common</p></td></tr><tr><td><p>hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury).</p></td><td><p>Very Rare</p></td></tr><tr><td rowspan="4"><p>Skin and subcutaneous tissue disorders</p></td><td><p>rash<sup>&Dagger;</sup></p></td><td><p>Common</p></td></tr><tr><td><p>bruising, urticaria, pruritus</p></td><td><p>Uncommon</p></td></tr><tr><td><p>angiooedema</p></td><td><p>Rare</p></td></tr><tr><td><p>erythema nodosum, erythema multiforme</p></td><td><p>Very Rare</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>arthralgia, myalgia including muscle cramps</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td><p>enuresis in children</p></td><td><p>Uncommon</p></td></tr><tr><td rowspan="2"><p>General disorders and administration site conditions</p></td><td><p>pyrexia<sup>&Dagger;</sup></p></td><td><p>Common</p></td></tr><tr><td><p>asthenia/fatigue, malaise, oedema</p></td><td><p>Uncommon</p></td></tr><tr><td colspan="3"><p>* Frequency Category: Defined for each Adverse Reaction by the incidence reported in the clinical trials data base:</p><p>Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000).</p><p><sup>&dagger;</sup> This adverse experience, reported as Very Common in the patients who received montelukast, was also reported as Very Common in the patients who received placebo in clinical trials.</p><p><sup>&Dagger;</sup> This adverse experience, reported as Common in the patients who received montelukast, was also reported as Common in the patients who received placebo in clinical trials.</p><p><sup>&sect;</sup> Frequency Category: Rare</p></td></tr></tbody></table><p><u>To reports any side effect(s):</u></p><ul><li><strong><em>Saudi Arabia:</em></strong></li></ul><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><ul><li>Fax: +966 11 2057662</li><li>Call NPC at +966 11 2038222, Exts: 2317 &ndash; 2356 &ndash; 2353 &ndash; 2354 &ndash; 2334 &ndash; 2340.</li><li>Toll free phone: 8002490000</li><li>Email: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul><p><strong>&nbsp;</strong></p><ul><li><strong><em>Other GCC States:</em></strong></li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks and in short term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences.<br />There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast. These include reports in adults and children with a dose as high as 1,000 mg (approximately 61 mg/kg in a 42-month old child).<br />The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients.<br />There were no adverse experiences in the majority of overdose reports.</p><p><u>Symptoms of overdose</u><br />The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.</p><p><u>Management of overdose</u><br />No specific information is available on the treatment of overdose with montelukast. It is not known whether montelukast is dialysable by peritoneal- or haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Leukotriene receptor antagonist<br />ATC-code: R03D C03</p><p><u>Mechanism of action</u><br />The cysteinyl leukotrienes (LTC<sub>4</sub>, LTD<sub>4</sub>, LTE<sub>4</sub>) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene (CysLT) receptors found in the human airway and cause airway actions, including bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment.</p><p><u>Pharmacodynamic effects</u><br />Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT<sub>1</sub> receptor. In clinical studies, montelukast inhibits bronchoconstriction due to inhaled LTD<sub>4</sub> at doses as low as 5 mg. Bronchodilation was observed within 2 hours of oral administration. The bronchodilation effect caused by a &beta;-agonist was additive to that caused by montelukast. Treatment with montelukast inhibited both early- and late-phase bronchoconstriction due to antigen challenge. Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and paediatric patients. In a separate study, treatment with montelukast significantly decreased eosinophils in the airways (as measured in sputum) and in peripheral blood while improving clinical asthma control.<u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u><br />In studies in adults, montelukast, 10 mg once daily, compared with placebo, demonstrated significant improvements in morning FEV<sub>1</sub> (10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant decrease in total &beta;-agonist use (-26.1% vs -4.6% change from baseline). Improvement in patient-reported daytime and nighttime asthma symptoms scores was significantly better than placebo.<br />Studies in adults demonstrated the ability of montelukast to add to the clinical effect of inhaled corticosteroid (% change from baseline for inhaled beclomethasone plus montelukast vs beclomethasone, respectively for FEV<sub>1</sub>: 5.43% vs 1.04%; &beta;-agonist use: -8.70% vs 2.64%). Compared with inhaled beclomethasone (200 &mu;g twice daily with a spacer device), montelukast demonstrated a more rapid initial response, although over the 12-week study, beclomethasone provided a greater average treatment effect (% change from baseline for montelukast vs beclomethasone, respectively for FEV<sub>1</sub>: 7.49% vs 13.3%; &beta;-agonist use: -28.28% vs -43.89%). However, compared with beclomethasone, a high percentage of patients treated with montelukast achieved similar clinical responses (e.g., 50% of patients treated with beclomethasone achieved an improvement in FEV<sub>1</sub> of approximately 11% or more over baseline while approximately 42% of patients treated with montelukast achieved the same response).<br />In a 12-week, placebo-controlled study in paediatric patients 2 to 5 years of age, montelukast 4 mg once daily improved parameters of asthma control compared with placebo irrespective of concomitant controller therapy (inhaled/nebulized corticosteroids or inhaled/nebulised sodium cromoglycate). Sixty percent of patients were not on any other controller therapy. Montelukast improved daytime symptoms (including coughing, wheezing, trouble breathing and activity limitation) and nighttime symptoms compared with placebo. Montelukast also decreased &ldquo;as needed&rdquo; &beta;-agonist use and corticosteroid rescue for worsening asthma compared with placebo. Patients receiving montelukast had more days without asthma than those receiving placebo. A treatment effect was achieved after the first dose.<br />In a 12-month, placebo-controlled study in paediatric patients 2 to 5 years of age with mild asthma and episodic exacerbations, montelukast 4 mg once daily significantly (p&le;0.001) reduced the yearly rate of asthma exacerbation episodes (EE) compared with placebo (1.60 EE vs. 2.34 EE, respectively), [EE defined as &ge;3 consecutive days with daytime symptoms requiring &beta;-agonist use, or corticosteroids (oral or inhaled), or hospitalisation for asthma]. The percentage reduction in yearly EE rate was 31.9%, with a 95% CI of 16.9, 44.1.<br />In a placebo-controlled study in paediatric patients 6 months to 5 years of age who had intermittent asthma but did not have persistent asthma, treatment with montelukast was administered over a 12-month period, either as a once-daily 4 mg regimen or as a series of 12-day courses that each were started when an episode of intermittent symptoms began. No significant difference was observed between patients treated with montelukast 4 mg or placebo in the number of asthma episodes culminating in an asthma attack, defined as an asthma episode requiring utilization of health-care resources such as an unscheduled visit to a doctor&#39;s office, emergency room, or hospital; or treatment with oral, intravenous, or intramuscular corticosteroid.<br />In an 8-week study in paediatric patients 6 to 14 years of age, montelukast 5 mg once daily, compared with placebo, significantly improved respiratory function (FEV<sub>1</sub> 8.71% vs 4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change from baseline) and decreased &ldquo;as-needed&rdquo; &beta;-agonist use (-11.7% vs +8.2% change from baseline).<br />In a 12-month study comparing the efficacy of montelukast to inhaled fluticasone on asthma control in paediatric patients 6 to 14 years of age with mild persistent asthma, montelukast was non-inferior to fluticasone in increasing the percentage of asthma rescue-free days (RFDs), the primary endpoint. Averaged over the 12-month treatment period, the percentage of asthma RFDs increased from 61.6 to 84.0 in the montelukast group and from 60.9 to 86.7 in the fluticasone group. The between group difference in LS mean increase in the percentage of asthma RFDs was statistically significant (-2.8 with a 95% CI of -4.7, -0.9), but within the limit pre-defined to be clinically not inferior. Both montelukast and fluticasone also improved asthma control on secondary variables assessed over the 12 month treatment period:<br />FEV<sub>1</sub> increased from 1.83 L to 2.09 L in the montelukast group and from 1.85 L to 2.14 L in the fluticasone group. The between-group difference in LS mean increase in FEV<sub>1</sub> was -0.02 L with a 95% CI of -0.06, 0.02. The mean increase from baseline in % predicted FEV<sub>1</sub> was 0.6% in the montelukast treatment group, and 2.7% in the fluticasone treatment group. The difference in LS means for the change from baseline in the % predicted FEV<sub>1</sub> was significant: -2.2% with a 95% CI of -3.6, -0.7.<br />The percentage of days with &beta;-agonist use decreased from 38.0 to 15.4 in the montelukast group, and from 38.5 to 12.8 in the fluticasone group. The between group difference in LS means for the percentage of days with &beta;-agonist use was significant: 2.7 with a 95% CI of 0.9, 4.5.<br />The percentage of patients with an asthma attack (an asthma attack being defined as a period of worsening asthma that required treatment with oral steroids, an unscheduled visit to the doctor&#39;s office, an emergency room visit, or hospitalisation) was 32.2 in the montelukast group and 25.6 in the fluticasone group; the odds ratio (95% CI) being significant: equal to 1.38 (1.04, 1.84).<br />The percentage of patients with systemic (mainly oral) corticosteroid use during the study period was 17.8% in the montelukast group and 10.5% in the fluticasone group. The between group difference in LS means was significant: 7.3% with a 95% CI of 2.9; 11.7.<br />Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12-week study in adults (maximal fall in FEV<sub>1</sub> 22.33% for montelukast vs 32.40% for placebo; time to recovery to within 5% of baseline FEV<sub>1</sub> 44.22 min vs 60.64 min). This effect was consistent throughout the 12-week study period. Reduction in EIB was also demonstrated in a short-term study in paediatric patients (maximal fall in FEV<sub>1</sub> 18.27% vs 26.11%; time to recovery to within 5% of baseline FEV<sub>1</sub> 17.76 min vs 27.98 min). The effect in both studies was demonstrated at the end of the once-daily dosing interval.<br />In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with montelukast, compared with placebo, resulted in significant improvement in asthma control (FEV<sub>1</sub> 8.55% vs -1.74% change from baseline and decrease in total &beta;-agonist use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u><br />Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated tablet, the mean peak plasma concentration (C<sub>max</sub>) is achieved 3 hours (T<sub>max</sub>) after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and C<sub>max</sub> are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10 mg film-coated tablet was administered without regard to the timing of food ingestion.<br />For the 5 mg chewable tablet, the C<sub>max</sub> is achieved in two hours after administration in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.<br />After administration of the 4 mg chewable tablet to paediatric patients 2 to 5 years of age in the fasted state, C<sub>max</sub> is achieved 2 hours after administration. The mean C<sub>max</sub> is 66% higher while mean C<sub>min</sub> is lower than in adults receiving a 10 mg tablet.</p><p><u>Distribution</u><br />Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of montelukast averages 8-11 litres. Studies in rats with radiolabelled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabelled material at 24 hours post-dose were minimal in all other tissues.</p><p><u>Biotransformation</u><br />Montelukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and children.<br />Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally, CYP 3A4 and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables of montelukast in healthy subjects that received 10 mg montelukast daily. Based on <em>in vitro </em>results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.</p><p><u>Elimination</u><br />The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabeled montelukast, 86% of the radioactivity was recovered in 5-day faecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.</p><p><u>Characteristics in Patients</u><br />No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (Child-Pugh score &gt;9).<br />With high doses of montelukast (20- and 60-fold the recommended adult dose), decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were observed which were transient in nature. The signs of toxicity in animals were increased excretion of saliva, gastrointestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150 mg/kg/day (&gt;232-fold the systemic exposure seen at the clinical dose). In animal studies, montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200 mg/kg/day (&gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals, was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.<br />No deaths occurred following a single oral administration of montelukast sodium at doses up to 5,000 mg/kg in mice and rats (15,000 mg/m<sup>2</sup> and 30,000 mg/m<sup>2</sup> in mice and rats, respectively), the maximum dose tested. This dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).<br />Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic exposure).<br />Montelukast was neither mutagenic in <em>in vitro</em> and <em>in vivo</em> tests nor tumorigenic in rodent species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose<br />Mannitol<br />Croscarmellose sodium<br />Ferric oxide red<br />Hydroxypropyl cellulose<br />Disodium EDTA<br />Purified water<br />Aspartame<br />Cherry flavor<br />Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.<br />Store in a dry place. Protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu -Alu blister pack of 10&rsquo;s tablets.<br />Pack size: Carton containing 3 blisters of 10 tablets each.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Pharmaceutical Industries
P.O. Box No.: 355127, Riyadh 11383
Kingdom of Saudi Arabia.
Tel: (+96611) 2650450, 2650354
Fax: (+96611) 2650383
Email: info@saudi-pharma.net
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>